Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone

Bone

Volumn 39, Issue 4, 2006, Pages 954-958

  Whitson, Heather E ^a,b   Lobaugh, Bruce ^b   Lyles, Kenneth W ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adverse effects; Clinical trial; Hypocalcemia; Metabolic bone disease; Risedronate

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; GLUCONATE CALCIUM; PARATHYROID HORMONE; PLACEBO; RISEDRONIC ACID; SALCATONIN; VITAMIN D; ZOLEDRONIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE REMODELING; BONE TURNOVER; CASE REPORT; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPOCALCEMIA; MULTICENTER STUDY; OSSIFICATION; PAGET BONE DISEASE; PARATHYROID FUNCTION; RANDOMIZED CONTROLLED TRIAL; TITRIMETRY; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL;

BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; HYPOCALCEMIA; MIDDLE AGED; OSTEITIS DEFORMANS;

EID: 33748171925     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.04.032     Document Type: Article

References (14)

1. Delmas P.D. Bisphosphonates in the treatment of bone diseases. N Engl J Med 335 (1996) 1836-1837
2. Lyles K.W., Siris E.S., Singer F.R., and Meunier P.J. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 16 (2001) 1379-1387
3. Conte P.F., Latreille J., Mauriac L., Calabresi F., Santos R., Campos D., et al. Delay in progression of bone metastasis in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 14 (1996) 2552-2559
4. Jodrell D., Iveson T., and Smith I.E. Symptomatic hypocalcemia after treatment with high-dose aminohydroxypropylidene diphosphate. Lancet 1 8533 (1987) 622 [Letter]
5. Varma N., and Kerrigan G.N.W. Electrocardiograpic Q-Tc prolongation associated with infusion of intravenous pamidronate disodium. Postgrad Med J 69 (1993) 497-498
6. McIntyre E., and Bruera E. Symptomatic hypocalcemia after intravenous pamidronate. J Palliat Care 12 (1996) 46-47
7. Chong G., Hoang T., and Davis I.D. Symptomatic hypocalcemia following intravenous pamidronate in cancer patients. Aust N Z J Med 29 (1999) 96-97
8. Sims E.C., Rogers P.B., Besser G.M., and Plowman P.N. Severe prolonged hypocalcemia following pamidronate for malignant hypercalcemia. Clin Oncol 10 (1998) 407-409
9. Mishra A., Wong L., and Jonklaas J. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 14 (2001) 159-164
10. Rosen C.J., and Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 348 (2003) 1503-1504
11. Stuckey B.G., Lim E.M., Kent G.N., Ward L.C., and Gutteridge D.H. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission. J Bone Miner Res 16 (2001) 1719-1723
12. Gutteridge D.H., Retallack R.W., Ward L.C., Stuckey B.G., Stewart G.O., Prince R.L., et al. Clinical, biochemical, hematologic, and radiographic response in Paget's disease following intravenous pamidronate disodium: a 2-year study. Bone 19 (1996) 387-394
13. Reid I.R., Miller P., Lyles K., Fraser W., Brown J.P., Saidi Y., et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's Disease. N Engl J Med 353 (2005) 898-908
14. Heaney R.P., Dowell M.S., Hale C.A., and Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22 (2003) 142-146